Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: I. Efficacy in Short-term Treatment
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Following promising preliminary evidence, the benzodiazepine-derivative alprazolam was studied in a large, placebo-controlled, eight-week, flexible-dose trial in patients with agoraphobia with panic attacks and panic disorder. Of 526 patients, 481 completed three weeks of treatment; however, significantly more placebo (102/234) than alprazolam (21/247) recipients subsequently dropped out of the trial, primarily citing ineffectiveness (of placebo) as the reason. Alprazolam was found to be effective and well tolerated. There were significant alprazolam-placebo differences in improvement for (1) spontaneous and situational panic attacks, (2) phobic fears, (3) avoidance behavior, (4) anxiety, and (5) secondary disability, all significant by the end of week 1. At the primary comparison point (week 4), 82% of the patients receiving alprazolam were rated moderately improved or better vs 43% of the placebo group. At that point, 50% of the alprazolam recipients vs 28% of placebo recipients were free of panic attacks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The US FDA’s approval for alprazolam came after 2 large, randomized, clinical trials that demonstrated short-term efficacy and clinically acceptable tolerability versus placebo (Ballenger et al., 1988; Klerman, 1988).”
From A Review of Alprazolam Use, Misuse, and Withdrawal (2018) · cites this paper as Ballenger et al., 1988
Citations
Cites
SCL-90: an outpatient psychiatric rating scale--preliminary report.
Derogatis, L. R., Lipman, R. S., & Covi, L. (1973) · PubMed · Cited by 3,800
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801
Delineation of two drug-responsive anxiety syndromes
Klein, D. F. (1964) · Psychopharmacologia · doi:10.1007/bf02193476 · Cited by 898
Treatment of Endogenous Anxiety With Phobic, Hysterical, and Hypochondriacal Symptoms
Sheehan, D. V. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140053006 · Cited by 729
PSYCHIATRIC REACTION PATTERNS TO IMIPRAMINE
KLEIN, D. F., & FINK, M. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.5.432 · Cited by 416
Treatment of Phobias: I. Comparison of Imipramine Hydrochloride and Placebo
Zitrin, C. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790020019002 · Cited by 342
Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine
Zitrin, C. M. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140065007 · Cited by 332
Major Depression in Patients With Agoraphobia and Panic Disorder
Breier, A. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790230015002 · Cited by 317
Chouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982) · Psychopharmacology · doi:10.1007/bf00464571 · Cited by 256
Behavior Therapy, Supportive Psychotherapy, Imipramine, and Phobias
Zitrin, C. M. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770270057005 · Cited by 246
Cited by
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Baxter, L. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090009002 · Cited by 1,293
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
The relation between alcohol problems and the anxiety disorders
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.6.685 · Cited by 724
Behavioral treatment of panic disorder
Barlow, D. H., Craske, M. G., Cerny, J. A., & Klosko, J. S. (1989) · Behavior Therapy · doi:10.1016/s0005-7894(89)80073-5 · Cited by 627
Metadata
- Authors
- Ballenger, J. C.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Ballenger, James C.
- ORCID
- Ballenger, James C.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1988-05-01
- Volume
- 45
- Issue
- 5
- Pages
- 413
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2068629053
- Cited by
- 564
- References
- 55
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 7 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 61.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- alprazolam, panic disorder, agoraphobia, benzodiazepines, panic attacks, phobic fear, avoidance behavior, anxiety, secondary disabilities, drug efficacy, tolerability
- MeSH terms
- Adolescent, Adult, Aged, Alprazolam, Anxiety Disorders, Clinical Trials as Topic, Double-Blind Method, Fear, Female, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Panic, Patient Dropouts, Placebos, Psychiatric Status Rating Scales, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: I. Efficacy in Short-term Treatment. https://app.cochat.ai/papers/10.1001/archpsyc.1988.01800290027004
- The paper
- Ballenger, J. C. (1988). Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: I. Efficacy in Short-term Treatment. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800290027004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.